181 results about "Glyceryl behenate" patented technology

The invention discloses a cleansing oil, which comprises the following components in parts by weight: 50-85 parts of grease, 5-30 parts of a polyglycerol emulsifying agent, 0.1-3 parts of phytosteryl/docosyl/octyldecanol lauryl glutamate, 0.1-4 parts of glyceryl behenate/eicosadioate, 0.1-5 parts of water, 0.01-0.2 part of an antioxidant, 0.01-0.2 part of a skin conditioner, 0.01-1.0 part of an essence, and 0.001-2 parts of a plant extractive solution. Through the addition of the special content of phytosteryl/docosyl/octyldecanol lauryl glutamate and the special content of glyceryl behenate/eicosadioate into plant-derived polyglycerol emulsifying agent and grease, the cleansing oil of the invention has excellent moisturizing and skin caring effects, but is not greasy, and does not cause skin allergy and irritation. Meanwhile, the cleansing oil has thixotropic property, so as to provide unique silk-like feeling during face skin massage.

Disclosed is an anhydrous lipstick comprising a combination of active ingredients comprising Portulaca pilosa extract, sunflower oil, jojoba esters, mango butter, and tocopherol and a dermatologically acceptable carrier comprising glyceryl behenate/eicosadioate.

The invention relates to a cefpodoxime proxetil dry suspension composition and a preparation method thereof. The invention provides the cefpodoxime proxetil dry suspension composition, containing 100 parts by weight of the cefpodoxime proxetil and 20 to 500 parts by weight of the glyceryl behenate. The invention also provides the preparation method of the dry suspension composition. The dry suspension composition of the invention is capable of reducing bitterness of the cefpodoxime proxetil remarkably and improving compliance of a clinical patient, thereby being suitable for a child to take a drug.

The invention discloses an oral prednisone time-selecting release preparation and a preparation method thereof. The oral prednisone time-selecting release preparation provided by the invention mainly consists of 0.3-5 parts of prednisone and derivatives thereof, 10-50 parts of glyceryl behenate and 3-30 parts of hydroxypropyl cellulose, and can further contain a disintegrating agent and other pharmaceutically acceptable excipients. The preparation method is as below: extruding tablet cores or granules containing the drug according to the formula by a tablet press or a dry granulator; and coating the tablet cores or particles containing the drug by a coating pan or a fluidized bed to attach the coating film to the tablet cores or particles containing the drug, so as to obtain the oral prednisone time-selecting release preparation. The oral prednisone time-selecting release preparation provided by the invention can achieve a good balance between the biological rhythm of the patients and the curative effects, and is safer, more convenient and effective compared with a traditional preparation. The oral prednisone time-selecting release preparation is prepared by an extrusion-coating process, which is simple for operation, and the obtained time-selecting release preparation has the advantages of drug stability and high reproducibility.

A waterproof liquid foundation formula and a preparation method thereof are provided. The formula comprises the following components: cyclopentasiloxane, isododecane, propylene glycol, isodecyl isononanoate, trimethylsiloxysilicate, polydimethylsiloxane crosslinked polymer, phenyl trimethicone, cetyl PEG/PPG-10/1 polydimethylsiloxane, polydimethylsiloxane, double-PEG/PPG-14/14 polydimethylsiloxane, silica, polymethyl methacrylate, boron nitride, glyceryl behenate/eicosadioate, magnesium sulfate, tocopheryl acetate, titanium dioxide, iron oxide yellow, iron oxide red, iron oxide black, phenoxyethanol and ethylhexyl glycerol. The waterproof liquid foundation forms a protective film on the surface of the skin, has a certain effect of isolating external damage and a long lasting effect on theskin, can well lighten pores and acne marks, and is non-irritating to the skin. The foundation has a good matte effect, which makes the makeup lasting and natural while evenly correcting the complexion.

An efficient seed germination promoting agent is characterized by being prepared from the following components in parts by weight: 90 to 110 parts of magnetized water, 1.5 to 2.5 parts of tea saponin, 1 to 2 parts of purple sweet potato anthocyanin, 1 to 2 parts of compound sodium nitrophenolate, 1.5 to 2.5 parts of purslane extract, 4 to 6 parts of alanine, 3 to 5 parts of potassium dihydrogen phosphate, 1 to 2 parts of borneol, 4 to 6 parts of tea water, 4 to 6 parts of 25% carbendazim wettable powder, 1.5 to 2.5 parts of ethanol, 1.5 to 2.5 parts of chelated iron, 0.4 to 0.6 part of glyceryl behenate, 1 to 2 parts of phosphoric buffer solution, 0.4 to 0.6 part of neutral protease, 3 to 5 parts of ammonia water, 1 to 2 parts of fulvic acid, 1.5 to 2.5 parts of gibberellin, 0.4 to 0.6 part of liquid paraffin, 1.5 to 2.5 parts of phoxim, 0.4 to 0.6 part of automobile anti-freezing liquid, 0.3 to 0.5 part of L-glutamic acid, 2 to 3 parts of activator, and 0.4 to 0.6 part of potassium sorbate. The provided seed germination promoting agent is nontoxic and harmless, has a sterilizing effect, and can promote the germination of paddy rice and increase the emergence rate. Moreover, there is no residue.

The invention relates to a light-emitting painted pottery glaze composition which is characterized in that the glaze material is prepared from the components of, by weight, 45-55 parts of nano-silica, 25-35 parts of electronic-grade red lead, 0.4-0.6 part of graphene, 0.4-0.6 part of glyceryl behenate, 0.4-0.6 part of hydroxypropyl-beta-cyclodextrin, 0.4-0.6 part of modified corn starch, 4-6 parts of copper oxide, 1-2 parts of polyethylene wax, 0.1-0.3 part of iron oxide, 1-3 parts of potassium feldspar micro-powder, 0.4-0.6 part of silver nitrate, and 1-3 parts of sea mud. The painted pottery fired with the glaze composition has a crystal clear, bright and smooth glaze, and an excellent decorative effect. With the modified sea mud, the glaze never peels from a finished product, and the product can be preserved permanently.

The invention discloses a nifedipine sustained release tablet for treating cardiovascular diseases and a preparation method thereof. Sustained release granules are prepared by adopting low-melting-point sustained release materials including glyceryl behenate, polyethylene glycol 4000 and nifedipine; use of an organic solvent is avoided; the nifedipine sustained release tablet disclosed by the invention is good for the environmental protection; potential hurt to patients caused by residual organic solvents is also avoided; the sustained release materials and active medicines form granules similar to solid dispersoid, so that sustained release of nifedipine is kept for a long time, and furthermore, rapid release of medicines in rapid release granules is not influenced. The nifedipine sustained release tablet disclosed by the invention is prepared by adopting the conventional granulating process; the complex production equipment and the production process are avoided; energy is saved; the production efficiency is greatly increased.

The invention discloses a medicinal cefetamet pivoxil hydrochloride composition for treating sensitive bacteria infectious diseases, and belongs to the field of medical technology. The medicinal cefetamet pivoxil hydrochloride composition is prepared from cefetamet pivoxil hydrochloride, compressible starch, microcrystalline cellulose 102, carboxymethyl starch sodium, hydroxypropylcellulose, glyceryl behenate and magnesium stearate. Experiments discover that compared with the prior art, the tablet prepared by novel crystal type compound of the cefetamet pivoxil hydrochloride is relatively low in high-molecular polymer content and good in stability; the increasing of the content of the high-molecular polymer is quite few with the increasing of storage time; meanwhile, the composition has more remarkable antimicrobial activity on pneumococcus and hemophilus influenzae as well as has relatively strong antimicrobial activity on enterococcus and staphylococcus.

The invention discloses a pig raising manure deodorization preparation. The pig raising manure deodorization preparation is characterized by comprising, by weight, 5 parts of tourmaline powder, 5 parts of glyceryl behenate, 10 parts of stearic acid, 3 parts of theophylline, 3 parts of curcumin, 3 parts of citric acid, 20 parts of lotus leaves, 10 parts of dried tangerine or orange peel, 5 parts of camphor, 10 parts of clove, 5 parts of pumpkin seeds, 5 parts of garland chrysanthemum, 10 parts of licorice, 5 parts of camellia, 5 parts of portulaca oleracea, 3 parts of coptis chinensis, 5 parts of bitter gourd, 3 parts of pagoda tree pod, 3 parts of peppermint roots, 10 parts of chili leaves, 5 parts of tilia bark and 500 parts of distilled water. The pig raising manure deodorization preparation has the advantages that effects of effectively removing smelly substances in pig raising manure can be realized by the pig raising manure deodorization preparation which is a deodorant, the pig raising manure deodorization preparation further has a sterilization function, accordingly, survival environments can be guaranteed to a certain extent while odor of the manure is removed, and the air freshness can be kept; the pig raising manure deodorization preparation is made of raw materials which are easily available, and is low in production and service costs.

A sildenafil citrate taste-masking preparation and a preparing method thereof are disclosed. The sildenafil citrate taste-masking preparation at least comprises, based on the total weight of tablets, 15-30% of sildenafil citrate, 30-65% of hydroxypropyl cellulose and 15-20% of glyceryl behenate. The preparing method includes: mixing a formula dosage of the sildenafil citrate and a formula dosage of the hydroxypropyl cellulose to prepare melt dispersion, cutting the melt dispersion into particles, grinding the particles together with the glyceryl behenate, fully mixing with other auxiliary materials, and tabletting into tablets for oral administration.

The invention provides a mesalazine enteric-coated sustained-release pellet, which consists of a slow-release pellet core and an enteric-coated dressing. The slow-release pellet core contains 40-45 wt.% of mesalazine, 45-50 wt.% of a matrix sustained-release composite, 5-10% of a chaotropic agent and 0-5 wt.% of other additives; the matrix sustained-release composite consists of glyceryl behenate and microcrystalline cellulose in the weight ratio of 2-4:1. The invention also provides a preparation method of the mesalazine enteric-coated sustained-release pellet. The method provided by the invention employs a skeleton controlled-release technology to control drug release, reaches ideal drug release rate and good inter-batch reproducibility in preparation, does not have high requirement on equipment, and is in favor of ndustrial production.

The invention provides gliclazide tablets (II) and a preparation method thereof, and belongs to the field of pharmaceutical preparations. According to the invention, glyceryl behenate is used as a lipid sustained-release matrix, is used as a sustained-release skeleton at the same time, and is subjected to fluidization granulation, so that solid bridges are formed among the raw materials, raw material powder is bonded, sustained-release particles are formed, the release of gliclazide can be effectively controlled, the phenomenon of sudden release of active ingredients is avoided, and the medication safety is guaranteed. Meanwhile, the glyceryl behenate is subjected to the fluidization granulation, no explosive solvent such as ethanol is required to be used for preparing an adhesive, no residual solvent is generated, and industrial mass production is facilitated.

The invention relates to a novel prescription and a preparation method of an oral paroxetine hydrochloride enteric controlled release tablet. The paroxetine hydrochloride enteric controlled release tablet consists of a double-layer core and an enteric coating, wherein the enteric coating enables active pharmaceutical ingredients to release in a fixed position at the lower end of the small intestine; the double-layer core controls the constant release speed of a medicine; the core consists of two layers, wherein one layer is a corroded blockage layer free of the active ingredients and is used for limiting the liquid permeation on the surface of a matrix, and another layer is a medicine-containing layer of a hydrophilic matrix; and when an aqueous medium enters a hydrophilic layer containing the active ingredients, a polymer can be hydrated and gelled, and thus a screen is constructed for the active ingredients to release and disperse from a preparation. The oral paroxetine hydrochloride enteric controlled release tablet is high in medicine release performance and completely meets the requirement on zero-order release. A controlled release material of a corroded layer is a mixture of docosanoic acid glycerol ester and/or ethyecellulose based on the mass ratio of 5: 1 to 1: 5; and the material adopted in the hydrophilic matrix layer is HPMC (Hydroxy Propyl Methyl Cellulose) series, and K4M is preferable.

The invention discloses gliclazide sustained-release tablets, which are prepared by evenly mixing drug-loading particles with pharmaceutically acceptable adjuvant materials and tabletting the obtained mixture; a preparation method of the drug-loading particles comprises the following steps: heating glyceryl behenate up to 65-70 DEG C for melting, then adding meglumine and evenly stirring in a heat preservation process, adding gliclazide and stirring until the mixture is molten, cooling for solidifying, and pelletizing, wherein the mass ratio of the gliclazide to the glyceryl behenate to the meglumine is equal to 1 to (1.5-4.5) to (0.1-0.3). The gliclazide sustained-release tablets are stable in drug release speed, better in drug stability, high in bioavailability, simple in preparation technology and suitable for industrial mass production.

A pharmaceutical composition comprising ramipril, another active agent, and a blending agent, wherein in the ramipril is coated by the blending agent, and wherein the blending agent is glyceryl behenate, glyceryl stearate, stearyl alcohol, macrogol stearate ether, palmitosearate, ethylene glycol, polyethylene glycol, stearic acid, cetyl alcohol, lauryl alcohol, amylopectin, poloxymer or combinations thereof.

The invention belongs to the field of sustained-release drug preparations, and particularly relates to a trimetazidine hydrochloride sustained release tablet taking glyceryl behenate as a framework material and a preparation method of the trimetazidine hydrochloride sustained release tablet. According to the main technical scheme disclosed by the invention, a sustained-release preparation is prepared from trimetazidine hydrochloride as an effective component, only glyceryl behenate as a sustained-release framework material and auxiliary materials such as a small amount of release speed regulator. According to the trimetazidine hydrochloride sustained release tablet provided by the invention, an in vitro release rate experiment shows that the drug release is not affected by the pH environment, compared with commercially available 'vasorel' (trimetazidine dihydrochloride tablet), the trimetazidine hydrochloride sustained release tablet has good similarity (f2 is greater than 65); and the Beagle pharmacokinetic experiment in dogs shows that the trimetazidine hydrochloride sustained release tablet has bioequivalence in comparison with 'vasorel'. One trimetazidine hydrochloride sustained release tablet provided by the invention is taken twice a day, and the trimetazidine hydrochloride sustained release tablet is convenient to take, has good medicine compliance in patients, and is capable of keeping steady state plasma concentration for a long period of time. The preparation method disclosed by the invention is simple and stable in process, and is easily put into volume production.

The invention relates to a compound amoxicillin and clavulanate potassium tablet and a preparation method thereof. The tablet consists of the following components in percentage by weight: 15 to 30 percent of amoxicillin, 5 to 15 percent of a clavulanate potassium mixture, 30 to 65 percent of a filler, 1.5 to 8 percent of crosslinked povidone, 0.6 to 3 percent of povidone K30, 1 to 3 percent of silica and 1 to 5 percent of glyceryl behenate. The preparation method comprises the following steps: adding the amoxicillin, the filler and the crosslinked povidone into a pelletizer, mixing and adding an adhesive in a mixing process; and adding the prepared amoxicillin granules and clavulanate potassium mixture, the silica and the glyceryl behenate into a mixing machine, mixing, discharging and tabletting. Although the compound amoxicillin and clavulanate potassium tablet adopts a half-wet method to pelletize, the clavulanate potassium is unlikely to degrade, so that the stability of a medicine is guaranteed effectively.

The invention discloses an ointment combination matrix for sustained-release drug delivery, and belongs to the technical field of a medicine preparation. The ointment combination matrix contains a hydrophilic surfactant, a cellulose derivative, glyceryl behenate and vaseline, wherein the matrix is ground and mixed with the medicine to prepare the ointment; the ointment is swelled under in vitro release conditions of 37 DEG C and 100rpm; the medicine is kept to release at zero level or similar zero level for a long period of time; vaseline is good in adaptability to body tissues, and has the effect of promoting wound healing; the hydrophilic surfactant absorbs body liquid, so that the combination matrix is swelled and a drug release channel can be formed; the glyceryl behenate is good in biocompatibility; the thermal stability is increased; and matrix dissolution is avoided and release of the drug is promoted due to an adhesive effect of the cellulose derivative. The ointment is suitable for dosing normal or damaged tissues, pollution and cleaning of corroded matters are avoided, the drug frequency is reduced, the medication compliance of a patient is improved, and the ointment is a sustained-release ointment preparation applied to skin, oral cavities, rectums, vaginas and the like.

Stable pharmaceutical compositions of fesoterodine or its pharmaceutically acceptable salt thereof and process for preparing the same. In a first embodiment, a stable pharmaceutical composition is provided comprising fesoterodine fumarate, glyceryl behenate and a stabilizer. The stable pharmaceutical tablet composition may further comprise i) fesoterodine fumarate in an 5 amount of 1% to 5% by weight, ii) glyceryl behenate in an amount of 1% to 8% by weight, iii) pregelatinized starch in an amount of 30% to 50% by weight and iv) a stabilizer in an amount of 0.1% to 10% by weight based on total weight of the composition.

The invention discloses a composition for improving stability of compound ibuprofen preparations. The composition comprises the following components in parts by weight: 200 parts of ibuprofen, 10 parts of phenylephrine hydrochloride, 4 parts of chlorpheniramine maleate, 14-56 parts of glyceryl behenate and 50-800 parts of additives. The compound ibuprofen preparation composition can be directly used for preparing compound ibuprofen solid preparations such as tablets, capsules or granules or can be mixed with a proper quantity of additives to prepare the compound ibuprofen solid preparations such as tablets, capsules or granules by virtue of processes of tabletting, filling capsules or split charging. The compound ibuprofen preparation composition can be used for greatly improving the stability of ibuprofen, phenylephrine hydrochloride and chlorpheniramine maleate; the quality of products can be improved; the effective periods of the products can be prolonged; the risk of clinical medication is reduced.